Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
APAC Approves “Good Submission Practice” Guidelines Aimed at Reducing Time to Approval in Asia
Executives of the Japan Pharmaceutical Manufacturers Association (JPMA) revealed at a press conference on April 10 that “Good Submission Practice” (GSubP) guidelines, which would help Asian drug makers to submit proper documents for new drug applications (NDAs), were approved at…
To read the full story
ORGANIZATION
- Global Pharma CEOs Urge Japan PM to Boost Support for Innovative Drugs
May 29, 2026
- Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
- FPMAJ Calls for Greater Support for Stable Drug Supplies in Honebuto Policy
May 22, 2026
- JPMA Exec Urges Broader Debate on Japan’s CEA System
May 22, 2026
- COVID-19 Vaccination Rates Fall as Out-of-Pocket Costs Rise: Jiji Survey
May 21, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…